Last reviewed · How we verify
Vonoprazan-Amoxicillin Dual Therapy
Vonoprazan inhibits gastric acid secretion while amoxicillin kills Helicobacter pylori bacteria, together eradicating H. pylori infection.
Vonoprazan inhibits gastric acid secretion while amoxicillin kills Helicobacter pylori bacteria, together eradicating H. pylori infection. Used for Helicobacter pylori infection eradication.
At a glance
| Generic name | Vonoprazan-Amoxicillin Dual Therapy |
|---|---|
| Sponsor | Nanjing First Hospital, Nanjing Medical University |
| Drug class | Potassium-competitive acid blocker (PCAB) + beta-lactam antibiotic combination |
| Target | H+/K+-ATPase (vonoprazan); bacterial cell wall peptidoglycan (amoxicillin) |
| Modality | Small molecule |
| Therapeutic area | Gastroenterology / Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
Vonoprazan is a potassium-competitive acid blocker (PCAB) that suppresses gastric acid production by inhibiting the H+/K+-ATPase pump, creating an environment hostile to acid-dependent pathogens and allowing antibiotics to work more effectively. Amoxicillin is a beta-lactam antibiotic that disrupts bacterial cell wall synthesis. Together, this dual therapy achieves high H. pylori eradication rates by combining acid suppression with direct bactericidal activity.
Approved indications
- Helicobacter pylori infection eradication
Common side effects
- Diarrhea
- Nausea
- Abdominal discomfort
- Headache
- Allergic reactions (amoxicillin-related)
Key clinical trials
- Efficacy and Safety of 14-Day Vonoprazan-Based Dual Therapy Versus Quadruple Therapy for Helicobacter Pylori Eradication: A Multicentre, Non-Inferiority Randomized Controlled Trial (NA)
- Dual Therapy With Vonoprazan Plus Amoxicillin or Doxycycline Versus Bismuth Quadruple Therapy for Helicobacter Pylori Eradication. (NA)
- Banxiaxiexin Decoction Combined With Vonoprazan-Amoxicillin Dual Therapy in H. Pylori Eradication (PHASE3)
- Fourteen-Day Vonoprazan-Based Dual Therapy With Amoxicillin as First-Line Helicobacter Pylori Treatment in Comparison With Extended Sequential Therapy (PHASE4)
- 7-day High-Dose Vonoprazan-amoxicillin Dual Therapy Versus 14-day Vonoprazan-amoxicillin Dual Therapy for H. Pylori (NA)
- Efficacies of Bismuth-amoxicillin-vonoprazan Triple Therapy, Vonoprazan-amoxicillin Dual Therapy and Proton Pump Inhibitor-based Standard Triple Therapy for Hp Eradication (NA)
- Efficacy and Safety of 7-day Triple Therapy Containing Amoxicillin and Tetracycline Versus 14-day Dual Therapy for Helicobacter Pylori Eradication
- Eradication of Helicobacter Pylori Improves Metabolic Syndrome Through Modulation of Gut Microbiota. (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: